(Novartis QGE031) A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE0312) in decreasing the sensitivity to peanuts in patients with peanut allergy
To evaluate the efficacy of ligelizumab 240mg and 120mg (SCq4w), compared to placebo, as measured by the proportion of participants who can tolerate a single dose of >600mg of peanut protein without dose-limiting symptoms during the DBPCFC at week 12